Comparable stake leader
VANGUARD CAPITAL MANAGEMENT LLC
SEC ownership of Jazz Pharmaceuticals plc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001232524.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
01 Jul 2026
- Public ticker
- JAZZ on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VANGUARD CAPITAL MANAGEMENT LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001232524
- Issuer location
- Dublin
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Jazz Pharmaceuticals plc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD CAPITAL MANAGEME...
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
01 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 5%
13D/G row: VANGUARD CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Quick read
VANGUARD CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 5%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
VANGUARD CAPITAL MANAGEMENT LLC
5%
Seamus Mulligan
2.1%
Bruce C. Cozadd
0.6%
Renee D. Gala
0.24%
Robert Iannone
0.14%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5%
|
$633,056,418
3,103,522 shares
|
$0 | 31 Mar 2026 |
| Seamus Mulligan |
3/4/5
Director
|
2.1%
|
$242,862,893
1,284,649 shares
|
— | 28 May 2026 |
| Bruce C. Cozadd |
3/4/5
Director
|
0.6%
|
$88,176,020
366,682 shares
|
-$24,900,269 | 01 Jul 2026 |
| Renee D. Gala |
3/4/5
President & CEO
|
0.24%
|
$27,858,597
147,361 shares
|
— | 30 Jun 2026 |
| Robert Iannone |
3/4/5
EVP, Global Head of R&D & CMO
|
0.14%
|
$16,089,478
85,107 shares
|
-$1,204,573 | 30 Jun 2026 |
| Philip L. Johnson |
3/4/5
EVP & Chief Financial Officer
|
0.09%
|
$10,668,280
56,431 shares
|
— | 30 Jun 2026 |
| Neena M. Patil |
3/4/5
EVP & Chief Legal Officer
|
0.08%
|
$9,239,062
48,871 shares
|
-$11,211,147 | 30 Jun 2026 |
| Samantha J. Pearce |
3/4/5
EVP, Chief Commercial Officer
|
0.08%
|
$9,057,574
47,911 shares
|
-$1,625,977 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$46,486,985.
Buys
$0
Insiders: 0
Sells
$46,486,985
Insiders: 10
Net
-$46,486,985
Shares: -248,503
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 248,503
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 27,197 | $0 | $6,451,071 | -$6,451,071 |
| 3-6 | 0 | 86,015 | $0 | $16,518,810 | -$16,518,810 |
| 6-9 | 0 | 123,791 | $0 | $21,991,854 | -$21,991,854 |
| 9-12 | 0 | 11,500 | $0 | $1,525,250 | -$1,525,250 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Jazz Pharmaceuticals plc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
Seamus Mulligan
Net 12M change
-$46,486,985
Latest report
01 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Seamus Mulligan | Director | $242,862,893 | Mixed | 28 May 2026 | ||
| Bruce C. Cozadd | Director | $88,176,020 | -$24,900,269 | -22% | Filing P/S | 01 Jul 2026 |
| Renee D. Gala | President & CEO | $27,858,597 | Mixed | 30 Jun 2026 | ||
| Robert Iannone | EVP, Global Head of R&D & CMO | $16,089,478 | -$1,204,573 | -7% | Mixed | 30 Jun 2026 |
| Philip L. Johnson | EVP & Chief Financial Officer | $10,668,280 | Mixed | 30 Jun 2026 | ||
| Neena M. Patil | EVP & Chief Legal Officer | $9,239,062 | -$11,211,147 | -55% | Mixed | 30 Jun 2026 |
| Samantha J. Pearce | EVP, Chief Commercial Officer | $9,057,574 | -$1,625,977 | -15% | Mixed | 30 Jun 2026 |
| Daniel N. Swisher Jr. | President and COO | $6,553,818 | Mixed | 03 Mar 2023 | ||
| Mary Elizabeth Henderson | SVP, Technical Operations | $5,248,128 | -$1,418,500 | -21% | Mixed | 05 Mar 2026 |
| Kenneth W. O'Keefe | Director | $5,236,405 | Mixed | 02 Dec 2025 | ||
| Heather Ann McSharry | Director | $4,446,209 | -$1,089,127 | -20% | Filing P/S | 22 May 2026 |
| Patrick G. Enright | Director | $3,623,976 | Mixed | 18 Aug 2025 | ||
| Kim Sablich | EVP, GM of U.S. | $3,392,584 | Mixed | 05 Jun 2023 | ||
| Norbert G. Riedel | Director | $3,389,568 | -$655,680 | -16% | Mixed | 27 Feb 2026 |
| Finbar Larkin | SVP, Technical Operations | $2,594,532 | Mixed | 03 Mar 2023 | ||
| Rick E. Winningham | Director | $2,311,100 | -$1,656,872 | -42% | Filing P/S | 22 May 2026 |
| Mark Douglas Smith | Director | $2,231,724 | -$266,746 | -11% | Filing P/S | 15 Jun 2026 |
| Peter Gray | Director | $1,914,181 | Mixed | 11 Aug 2023 | ||
| Anne ORiordan | Director | $1,835,615 | Mixed | 07 Aug 2025 | ||
| Catherine A. Sohn | Director | $1,771,225 | Mixed | 11 Aug 2023 |
Recent insider transactions for Jazz Pharmaceuticals plc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Sale | -1.61% | $1,442,820 | $240.47 | -6,000 | 366,682 | 01 Jul 2026 | Direct |
| Samantha J. Pearce | JAZZ | Ordinary Shares | Tax liability | -5.01% | -2,527 | 47,911 | 30 Jun 2026 | Direct | ||
| Renee D. Gala | JAZZ | Ordinary Shares | Tax liability | -3.18% | -4,835 | 147,361 | 30 Jun 2026 | Direct | ||
| Robert Iannone | JAZZ | Ordinary Shares | Tax liability | -4.24% | -3,764 | 85,107 | 30 Jun 2026 | Direct | ||
| Neena M. Patil | JAZZ | Ordinary Shares | Tax liability | -5.2% | -2,678 | 48,871 | 30 Jun 2026 | Direct | ||
| Philip L. Johnson | JAZZ | Ordinary Shares | Tax liability | -5.59% | -3,343 | 56,431 | 30 Jun 2026 | Direct | ||
| Mark D. Smith | JAZZ | Ordinary Shares | Sale | -10.7% | $266,746 | $230.55 | -1,157 | 9,680 | 15 Jun 2026 | Direct |
| Neena M. Patil | JAZZ | Ordinary Shares | Sale | -2.27% | $278,196 | $231.83 | -1,200 | 51,549 | 10 Jun 2026 | Direct |
| Renee D. Gala | JAZZ | Ordinary Shares | Gift | -0.39% | -600 | 152,196 | 03 Jun 2026 | Direct | ||
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Sale | -1.58% | $1,410,720 | $235.12 | -6,000 | 372,682 | 01 Jun 2026 | Direct |
| Samantha J. Pearce | JAZZ | Ordinary Shares | Sale | -12.1% | $1,625,977 | $235.41 | -6,907 | 50,272 | 28 May 2026 | Direct |
| Samantha J. Pearce | JAZZ | Ordinary Shares | Options Exercise | 13.7% | 6,907 | 57,179 | 28 May 2026 | Direct | ||
| Samantha J. Pearce | JAZZ | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -6,907 | 0 | 28 May 2026 | Direct | ||
| Seamus Mulligan | JAZZ | Ordinary Shares | Options Exercise | 0.29% | 3,415 | 1,183,028 | 28 May 2026 | Direct | ||
| Seamus Mulligan | JAZZ | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -3,415 | 0 | 28 May 2026 | Direct | ||
| Neena M. Patil | JAZZ | Ordinary Shares | Sale | -2.21% | $282,468 | $236.97 | -1,192 | 52,626 | 28 May 2026 | Direct |
| Rick E. Winningham | JAZZ | Ordinary Shares | Sale | -22.3% | $662,143 | $241.57 | -2,741 | 9,567 | 22 May 2026 | Direct |
| Rick E. Winningham | JAZZ | Ordinary Shares | Options Exercise | 38.4% | 3,415 | 12,308 | 22 May 2026 | Direct | ||
| Rick E. Winningham | JAZZ | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -3,415 | 0 | 22 May 2026 | Direct | ||
| Heather Ann McSharry | JAZZ | Ordinary Shares | Sale | -9.78% | $482,000 | $241.00 | -2,000 | 18,449 | 22 May 2026 | Direct |
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Sale | -1.56% | $1,219,980 | $203.33 | -6,000 | 378,682 | 01 May 2026 | Direct |
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Sale | -1.54% | $1,143,010 | $190.50 | -6,000 | 384,682 | 01 Apr 2026 | Direct |
| Patricia Carr | JAZZ | Ordinary Shares | Sale | -16.5% | $235,444 | $182.94 | -1,287 | 6,512 | 09 Mar 2026 | Direct |
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Tax liability | -3.72% | -15,114 | 390,682 | 05 Mar 2026 | Direct | ||
| Philip L. Johnson | JAZZ | Ordinary Shares | Tax liability | -4.2% | -2,615 | 59,608 | 05 Mar 2026 | Direct | ||
| Mary Elizabeth Henderson | JAZZ | Ordinary Shares | Tax liability | -4.85% | -1,394 | 27,334 | 05 Mar 2026 | Direct | ||
| Samantha J. Pearce | JAZZ | Ordinary Shares | Tax liability | -4.74% | -2,503 | 50,272 | 05 Mar 2026 | Direct | ||
| Robert Iannone | JAZZ | Ordinary Shares | Tax liability | -6.53% | -6,209 | 88,871 | 05 Mar 2026 | Direct | ||
| Patricia Carr | JAZZ | Ordinary Shares | Tax liability | -15.6% | -1,436 | 7,799 | 05 Mar 2026 | Direct | ||
| Renee D. Gala | JAZZ | Ordinary Shares | Tax liability | -4.42% | -7,065 | 152,630 | 05 Mar 2026 | Direct | ||
| Neena M. Patil | JAZZ | Ordinary Shares | Tax liability | -8.5% | -5,000 | 53,818 | 05 Mar 2026 | Direct | ||
| Bruce C. Cozadd | JAZZ | Ordinary Shares | Sale | -1.46% | $1,118,613 | $186.44 | -6,000 | 405,796 | 03 Mar 2026 | Direct |
| Norbert G. Riedel | JAZZ | Ordinary Shares | Sale | -32.7% | $655,680 | $192.00 | -3,415 | 7,024 | 27 Feb 2026 | Direct |
| Norbert G. Riedel | JAZZ | Ordinary Shares | Options Exercise | 48.6% | 3,415 | 10,439 | 27 Feb 2026 | Direct | ||
| Norbert G. Riedel | JAZZ | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -3,415 | 0 | 27 Feb 2026 | Direct | ||
| Patricia Carr | JAZZ | Ordinary Shares | Sale | -10.8% | $213,243 | $190.91 | -1,117 | 9,235 | 27 Feb 2026 | Direct |
| Philip L. Johnson | JAZZ | Ordinary Shares | Award | 23.5% | 11,857 | 62,223 | 26 Feb 2026 | Direct | ||
| Samantha J. Pearce | JAZZ | Ordinary Shares | Award | 22.8% | 9,782 | 52,775 | 26 Feb 2026 | Direct | ||
| Robert Iannone | JAZZ | Ordinary Shares | Award | 18.5% | 14,822 | 95,080 | 26 Feb 2026 | Direct | ||
| Patricia Carr | JAZZ | Ordinary Shares | Sale | -10.8% | $243,222 | $194.11 | -1,253 | 10,352 | 26 Feb 2026 | Direct |
| Patricia Carr | JAZZ | Ordinary Shares | Award | 23.7% | 2,223 | 11,605 | 26 Feb 2026 | Direct | ||
| Renee D. Gala | JAZZ | Ordinary Shares | Award | 38.6% | 44,465 | 159,695 | 26 Feb 2026 | Direct | ||
| Ted W. Love | JAZZ | Ordinary Shares | Award | 1,527 | 1,527 | 26 Feb 2026 | Direct | |||
| Neena M. Patil | JAZZ | Ordinary Shares | Award | 14.7% | 10,079 | 78,470 | 26 Feb 2026 | Direct | ||
| Neena M. Patil | JAZZ | Ordinary Shares | Sale | -49.4% | $10,650,482 | $191.56 | -55,600 | 56,862 | 26 Feb 2026 | Direct |
| Neena M. Patil | JAZZ | Ordinary Shares | Options Exercise | 154.8% | 51,000 | 83,946 | 26 Feb 2026 | Direct | ||
| Neena M. Patil | JAZZ | Non-Qualified Stock Option (right to buy) | Options Exercise | -100% | -47,209 | 0 | 26 Feb 2026 | Direct | ||
| Neena M. Patil | JAZZ | Incentive Stock Option (right to buy) | Options Exercise | -100% | -3,791 | 0 | 26 Feb 2026 | Direct | ||
| Mary Elizabeth Henderson | JAZZ | Ordinary Shares | Sale | -15.7% | $1,039,134 | $194.49 | -5,343 | 28,728 | 26 Feb 2026 | Direct |
| Mary Elizabeth Henderson | JAZZ | Ordinary Shares | Award | 15% | 4,447 | 34,071 | 26 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.